Cue Biopharma, Inc. (CUE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$35.73
Price Target
—
Target Range
— — —
Analyst Rating
—
Forward P/E—
Trailing P/E-4.3x
Forward PEG—
Implied Growth—
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
CUE Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Cue Biopharma, Inc. (CUE) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $94M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CUE trades at a trailing P/E of -4.3x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+202.1%
Avg Forward P/E17.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 AGIOAgios Pharmaceuticals, Inc. | $1.6B | $27.53 | $37.75 | +37.1% | Buy | — | 29 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $6.9B | $43.02 | $39.00 | -9.4% | Buy | 32.3x | 13 |
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 AGENAgenus Inc. | $132M | $3.75 | $7.33 | +95.5% | Buy | 1.8x | 11 |
 FATEFate Therapeutics, Inc. | $280M | $2.43 | $39.50 | +1525.5% | Buy | — | 31 |
 ALKSAlkermes plc | $5.9B | $35.40 | $44.00 | +24.3% | Buy | — | 28 |
 XNCRXencor, Inc. | $903M | $12.31 | $32.33 | +162.6% | Buy | — | 27 |
Upside Potential Comparison
FATEXNCRAGENIMVTNKTRKYMRAGIOALKSSee CUE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CUE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CUE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCUE — Frequently Asked Questions
Quick answers to the most common questions about buying CUE stock.
What is the CUE stock price target for 2026?
The consensus price target for CUE is $N/A, close to the current price of $35.73 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is CUE a buy, sell, or hold?
CUE has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is CUE stock overvalued or undervalued?
CUE's current price is $35.73 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can CUE stock go?
The most bullish Wall Street analyst has a price target of $N/A for CUE, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CUE stock?
CUE is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CUE stock forecast?
The 12-month CUE stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy CUE stock?
CUE appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CUE price targets vary so much?
CUE analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.